More Than Just Heartburn: Does Famotidine Effectively Treat Patients with COVID-19?

Key Messages

This editorial discusses retrospective studies that did not find any association between COVID-19 patients taking famotidine and improved symptoms.

The author points out the low dose of famotidine (20-40 mg/day) taken by the study participants, and could be much lower than the amount needed to affect SARS-CoV-2 activity.

The editorial implies that inadequate knowledge of unknown factors that may be affecting the retrospective studies has the potential to produce artifacts, which in this case may be the lack of any association between taking famotidine and improvement of COVID-19 symptoms,

At least one relevant retrospective study mentioned in the article is affected by the presence of such problems.

According to the author, studies which investigate the use of higher oral doses of famotidine - 60 mg, 3 times a day or higher - would be particularly useful for examining the potential of famotidine as a treatment for COVID-19.

Digestive Diseases and Sciences

Publication Date: February 24, 2021
Peer Reviewed: No
Publication Type: Review/Commentary/Letter
DOI: https://www.doi.org/10.1007/s10620-021-06875-w

More Than Just Heartburn: Does Famotidine Effectively Treat Patients with COVID-19?

Robert W. Malone